Gliomatosis Cerebri Diagnosis and Management Techniques

Gliomatosis cerebri is a rare, diffusely infiltrative glial neoplasm defined by extensive involvement of multiple cerebral lobes. Its presentation is often subtle, with nonspecific symptoms such as headache, seizures and cognitive changes, complicating early detection. Diagnosis relies predominantly on advanced neuroimaging, notably magnetic resonance imaging (MRI) with fluid-attenuated inversion recovery (FLAIR) sequences, which reveal widespread hyperintense signals without discrete mass effect. Complementary modalities—magnetic resonance spectroscopy (MRS) and positron emission tomography—provide metabolic and perfusion insights that guide differential diagnosis against encephalitis and other diffuse gliomas. Histopathological confirmation via stereotactic biopsy remains the gold standard, enabling molecular profiling that informs prognosis and therapeutic planning. Management is challenging: surgical resection is generally unfeasible, radiotherapy offers modest benefit and conventional chemotherapy has limited efficacy. Recent advances in alkylating agents, targeted therapies and immunomodulatory strategies are under investigation, emphasising a personalised, multidisciplinary approach. Despite poor overall survival, incremental improvements in imaging accuracy and molecular classification are refining patient stratification and may pave the way for more effective interventions.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Gliomatosis Cerebri Diagnosis and Management Techniques publication trend

The graph below shows the total number of articles in gliomatosis cerebri diagnosis and management techniques across all publications each year (not limited to Nature Index journals).

Technical terms

Gliomatosis cerebri: A diffusely infiltrating glial tumour involving at least two cerebral lobes without a discrete mass.
Fluid-attenuated inversion recovery (FLAIR): An MRI sequence that suppresses cerebrospinal fluid signals to enhance detection of parenchymal lesions.
Magnetic resonance spectroscopy (MRS): A non-invasive technique measuring brain metabolites to distinguish neoplastic from non-neoplastic tissue.
Stereotactic biopsy: A minimally invasive procedure using three-dimensional coordinates to obtain targeted brain tissue samples.
Temozolomide: An oral alkylating chemotherapeutic agent commonly used in diffuse glioma management.

References

1. Gliomatosis Cerebri: Current Understanding and Controversies. Frontiers in Oncology (2017).
2. Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC Cancer (2010).
3. Gliomatosis cerebri mimicking acute viral encephalitis and with malignant transformation of partial lesions: A case report. Experimental and Therapeutic Medicine (2014).
4. Clinical Manifestations and Imaging Characteristics of Gliomatosis Cerebri with Pathological Confirmation. Asian Pacific Journal of Cancer Prevention (2014).